Global Fluzoparib Market Strategic Research Report

Scope of the Report

The global Fluzoparib market size is predicted to grow from US$ 42.06 million in 2025 to US$ 113 million in 2032; it is expected to grow at a CAGR of 8.1% from 2026 to 2032.

Fluzoparib is an oral small-molecule targeted anticancer drug that belongs to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. It works by inhibiting PARP enzyme activity, blocking the repair of single-strand DNA breaks in tumor cells, thereby leading to the accumulation of DNA damage and ultimately inducing tumor cell death. Fluzoparib is mainly used for the treatment of solid tumors such as ovarian cancer and breast cancer in patients with BRCA gene mutations, and it plays an important role in maintenance therapy and the treatment of recurrent tumors. The drug is characterized by convenient oral administration and strong targeting ability, but it may also cause adverse reactions such as anemia, nausea, and fatigue.In 2025, Global Fuzuloparib Production Reached Approximately 1.2 Million units.

Fluzoparib, as a domestically developed PARP inhibitor, has rapidly emerged in China’s targeted anti-tumor therapy market in recent years. Developed by Hengrui Pharmaceuticals, the drug is primarily used for the treatment of BRCA mutation-related tumors such as ovarian cancer, benchmarking against international products like Olaparib. With the advancement of precision medicine and the increasing adoption of genetic testing, the eligible patient population for PARP inhibitors continues to expand, driving sustained growth in demand for fluzoparib. At the same time, inclusion in national medical insurance negotiations has significantly reduced patients’ financial burden and improved drug accessibility, enhancing its competitiveness in the domestic market. From a competitive landscape perspective, fluzoparib has gradually gained market share against imported drugs due to its pricing advantage and strong local distribution channels. However, multiple PARP inhibitors from both domestic and international companies are being launched or are in late-stage clinical development, intensifying market competition. Looking ahead, the growth potential of fluzoparib will largely depend on the expansion of indications (such as breast cancer and prostate cancer), combination therapy strategies, and the accumulation of real-world evidence. Overall, driven by supportive policies and strong clinical demand, the fluzoparib market still holds significant growth potential, although it faces long-term challenges in innovation and differentiation.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Fluzoparib market?

What factors are driving Fluzoparib market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Fluzoparib market opportunities vary by end market size?

How does Fluzoparib break out by Type, by Application?

This report presents a comprehensive overview of the global Fluzoparib market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 50 Mg
• 100 Mg

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Ovarian Cancer Treatment
• Breast Cancer
• Prostate Cancer
• Pancreatic Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Fluzoparib market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Ovarian Cancer Treatment, Breast Cancer, Prostate Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact